Sign In
Buy KTOV
$2.94
+0 (+0%)
At Close: Aug 17, 2022
Kitov Pharma Announces Closing of FameWave Acquisition
12:30pm, Wednesday, 08'th Jan 2020
TEL AVIV, Israel, Jan. 08, 2020 (GLOBE NEWSWIRE) -- Kitov Pharma Ltd. (“Kitov”) (NASDAQ/TASE: KTOV), a clinical-stage company advancing first-in-class therapies to overcome tumor immune evasi
Kitov Pharma Granted Additional 180-day Extension by Nasdaq to Comply with Bid Price Rule
12:00pm, Wednesday, 08'th Jan 2020
Kitov Pharma Ltd. (“Kitov”) (NASDAQ/TASE: KTOV), a clinical-stage company advancing first-in-class therapies to overcome tumor immune evasion and drug resistance, today announced that, after its
In the amended agreement with Coeptis, Kitov will receive up to $99.5M in milestone and reimbursement payments plus 20% in royaltiesCoeptis Pharmaceuticals has engaged a.
Kitov Pharma Appoints Eric K. Rowinsky, M.D., as Chairman of its Board
12:20pm, Wednesday, 02'nd Oct 2019
TEL AVIV, Israel, Oct. 02, 2019 (GLOBE NEWSWIRE) -- Kitov Pharma Ltd. (“Kitov”) (NASDAQ/TASE: KTOV), a clinical-stage company advancing first-in-class therapies to overcome tumor immune evasio
Kitov Pharma Presents Newly Released Data for NT-219 in Reversing Pancreatic Cancer Drug Resistance
12:30pm, Monday, 09'th Sep 2019
Kitov Pharma Ltd. (“Kitov”) (NASDAQ/TASE: KTOV), a clinical-stage company advancing first-in-class therapies to overcome tumor immune evasion and drug resistance, presented newly released proof-of
Kitov Pharma to Present at the H.C. Wainwright 21st Annual Healthcare Conference
12:22pm, Tuesday, 03'rd Sep 2019
TEL AVIV, Israel, Sept. 03, 2019 -- Kitov Pharma Ltd. (“Kitov”) (NASDAQ/TASE: KTOV), a clinical-stage company advancing first-in-class therapies to overcome tumor immune.
TEL AVIV, Israel, Aug. 29, 2019 (GLOBE NEWSWIRE) -- Kitov Pharma Ltd. (“Kitov”) (NASDAQ/TASE: KTOV), a clinical-stage company advancing first-in-class therapies to overcome tumor immune evasio
Kitov Pharma Announces Significant Progress in Closing of FameWave Acquisition Deal
12:24pm, Friday, 16'th Aug 2019
TEL AVIV, Israel, Aug. 16, 2019 (GLOBE NEWSWIRE) -- Kitov Pharma Ltd. (“Kitov”) (NASDAQ/TASE: KTOV), a clinical-stage company advancing first-in-class therapies to overcome tumor immune evasio
Administrative Enforcement Agreement Finalized between Kitov Pharma and the Israeli Securities Authority
12:20pm, Wednesday, 14'th Aug 2019
TEL AVIV, Israel, Aug. 14, 2019 (GLOBE NEWSWIRE) -- Kitov Pharma Ltd. (“Kitov”) (NASDAQ/TASE: KTOV), a clinical-stage company advancing first-in-class therapies to overcome tumor immune evasio
